About
Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.
Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.
Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.
Funding history · 3 rounds · $8.2M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Trobix Bio's primary focus in the biotech field?
- Trobix Bio is an Israeli biotech company focused on pioneering the human microbiome field. It uses its TBX™ technology platform, which incorporates CRISPR, phage, and synthetic biology, to develop orally administered precision oncology therapeutics.
- Which organization is Trobix Bio a spin-off from?
- Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.
- What are Trobix Bio's preclinical products and their intended uses?
- Trobix Bio's preclinical products are TBX201 and TBX301. TBX201 is being developed to reduce severe diarrhea in patients receiving irinotecan, while TBX301 aims to reduce colitis in patients receiving checkpoint inhibitors.
- When was Trobix Bio founded and where is its headquarters located?
- Trobix Bio was founded in March 2019 and is headquartered in Netanya, Israel.
- What was Trobix Bio's first funding round and who were the investors?
- In March 2019, Trobix Bio completed a Seed funding round, with Momentum Fund and The Chartered Group participating as investors.
- When did Trobix Bio receive its most recent Series A funding, and from whom?
- In March 2023, Trobix Bio received a Series A funding round from The Chartered Group.
- What is the total amount of funding Trobix Bio has raised to date?
- According to startupim data, Trobix Bio has raised a total of $8,200,000 USD.
- What is the current employee count for Trobix Bio?
- Trobix Bio currently has 6 employees.
- What is the status of Trobix Bio's website?
- Trobix Bio's website, https://www.trobix.bio/, is currently suspended.